Navigation Links
Greenphire CEO Sam Whitaker speaks on Sunshine Act and Clinical Trial Payments
Date:12/4/2012

KING OF PRUSSIA, Pa., Dec. 4, 2012 /PRNewswire-iReach/ -- Greenphire CEO Sam Whitaker spoke at the Sunshine Act and Aggregate Spend Bootcamp on the implications of the Physician Sunshine Act for the management of clinical trial payments and on advances in technology which streamlines financial reporting required to comply with the Act. 

The discussion focused on how pharmaceutical, biotech, and medical device companies can use technology to gather and report on required data on clinical trial payments, which present a particular tracking challenge because each clinical trial may involve a complex series of payments made to multiple physician investigators across multiple clinical sites.  To further complicate matters, payments may be made directly or by third parties like Contract Research Organizations (CROs).  Sam's discussion also focused on best practices in preparing for the Act and on the ancillary benefits to sponsor organizations of implementing data aggregation technologies across clinical trials, which include increased automation, tracking, and accountability, and reduced costs and risk.

The presentation took place on Tuesday, December 4, 2012 in Philadelphia, PA.  The Sunshine and Aggregate Spend Bootcamp is an intensive, hands-on seminar intended to prepare pharmaceutical and medical device companies for the requirements of complying with aggregate spend reporting under the Physician Sunshine Act.

About Greenphire

Greenphire is the industry's leading provider of clinical payment technology, designed to change the way research professionals work. We leverage our proprietary workflow automation and advanced web‐based payment technologies to help our clients improve operational efficiency, reduce costs, mitigate regulatory risks, increase subject retention and compliance, and produce quantifiable results that improve clinical operations and strategic planning. Learn more at www.greenphire.com.

Media Contact: Shana Jalbert Greenphire, (215) 948-9260, shana.jalbert@greenphire.com

News distributed by PR Newswire iReach: https://ireach.prnewswire.com


'/>"/>
SOURCE Greenphire
Copyright©2012 PR Newswire.
All rights reserved

Related biology news :

1. Autism Speaks announces the release of new genetic data for researchers
2. Autism Speaks and SAGE® Labs develop rat models for translational autism research
3. Autism Speaks awards nearly $2.9 million to fund autism research
4. Autism Speaks awards $1.1 million to fund high priority studies
5. Plant DNA speaks English, identifies new species
6. Sunshine, biofuel and the tides, oh my!
7. TESARO and Virginia G. Piper Cancer Center announce first patient in clinical trial of TSR-011
8. Clinical hypnosis can reduce hot flashes after menopause, Baylor study shows
9. BioLife Solutions Products Now Used in More than 50 Clinical Trial-Stage Cellular Therapies
10. Advanced Clinical Joins MedNet Solutions iMedNet Partner Program
11. New Market Forecasts Available for Critical Global Biotechnology Testing and Screening Markets: Molecular Diagnostics, Hematology, Clinical Chemistry and Nucleic Acid Testing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... India , April 28, 2016 ... Infosys (NYSE: INFY ), and Samsung SDS, a ... that will provide end customers with a more secure, ... services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ) , ... services, but it also plays a fundamental part in enabling ...
(Date:4/26/2016)... 27, 2016 Research and ... Biometrics Market 2016-2020"  report to their offering.  , ... The analysts forecast the global multimodal biometrics ... during the period 2016-2020.  Multimodal biometrics ... such as the healthcare, BFSI, transportation, automotive, and ...
(Date:4/15/2016)... DUBLIN , April 15, 2016 ... of the,  "Global Gait Biometrics Market 2016-2020,"  report ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The global gait ... CAGR of 13.98% during the period 2016-2020. ... movement angles, which can be used to compute ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... DIEGO , June 24, 2016 ... more sensitively detects cancers susceptible to PARP inhibitors ... circulating tumor cells (CTCs). The new test has ... HRD-targeted therapeutics in multiple cancer types. ... targeting DNA damage response pathways, including PARP, ATM, ...
(Date:6/23/2016)... ... June 23, 2016 , ... Mosio, a leader in clinical ... Patient Recruitment and Retention Tips.” Partnering with experienced clinical research professionals, Mosio revisits ... tips, tools, and strategies for clinical researchers. , “The landscape of how patients ...
(Date:6/23/2016)... , June 23, 2016 /PRNewswire/ - FACIT ... Ontario biotechnology company, Propellon Therapeutics ... development and commercialization of a portfolio of first-in-class ... Epigenetic targets such as WDR5 represent an exciting ... significantly in precision medicine for cancer patients. Substantial ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology: